MedTrace Logo

Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients

NCT04864366 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-03-15

No results posted yet for this study

Summary

The objective of this clinical study was to observe the changes of HBsAg levels after a sequential 48 weeks-treatment of TAF in ETV experienced CHB patients and to monitor the levels of cytokines such as IFN-λ3, IP-10, IL-12, IL-10, and IL-21.

Conditions

Interventions

DRUG

Tenofovir Alafenamide 25 MG [Vemlidy]

TAF is administered as a 25mg/tablet, taken orally with food once daily, for 48 weeks.

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Jiming Zhang, M.D. · Huashan Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2023-10-27
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04864366 on ClinicalTrials.gov